A pair of automated antibody tests created by Ortho Clinical Diagnostics to track down COVID-19 will be further developed thanks to a new partnership between the company and the Biomedical Advanced Research and Development Authority (BARDA).
The tests are known as VITROS Anti-SARS-COV-2 Total test and the VITROS Anti-SARS-COV-2 IgG test. The total test detects all COVID-19 related antibodies, while the IgG test charts only IgG antibodies. These appear in patients’ blood during late-phase infections and remain well after recovery. Such tests, therefore, allow medical personnel to track, surveil, and identify people who may have since recovered from COVID-19 and never realized they had it.
This would also allow for more potential donors of convalescent plasma to be found. Such plasma can be used as a possible treatment for those hospitalized with COVID-19.
Ortho’s tests have a distinct advantage as well: the analyzers on which they run are already installed in more than 1,000 hospitals and labs across the U.S. These analyzers are high-throughput, random access, and fully automated.
With assistance from BARDA, Ortho plans to begin manufacturing millions of tests per week.
A group of seven U.S. representatives recently wrote to Defense Secretary Lloyd Austin in a…
As more governments and businesses seek what artificial intelligence (AI) can offer, U.S. Reps. Troy…
A group of 14 U.S. senators recently called on the U.S. Senate Appropriations Subcommittee on…
In approving the Coast Guard Authorization Act of 2024 (H.R. 7659), the House recently authorized…
The U.S. Commerce Department recently added 37 Chinese entities to the Export Administration Regulations (EAR)…
In introducing the DHS Better Ballistic Body Armor Act (S. 4305) this month, U.S. Sens.…
This website uses cookies.